NCT06393465View on ClinicalTrials.gov

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy

Active, not recruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

June 15, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Interventions
DRUG

Tafamidis

61 milligrams under real world conditions

Trial Locations (1)

10001

Pfizer, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06393465 - Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy | Biotech Hunter | Biotech Hunter